U.S. Stock News

NasdaqGS:QLYS
NasdaqGS:QLYSSoftware

Qualys (QLYS) Beat Expectations And Raised Guidance, Is The Upside Already Priced In?

Qualys (QLYS) is back in focus after second quarter results topped market expectations, supported by demand for its AI driven risk operations platform, the new InstaScan capability, and higher full year guidance. See our latest analysis for Qualys. The latest move in Qualys reflects a mixed near term reaction and strong recent momentum, with the share price down 5.02% over the last day but showing a 16.78% 30 day share price return and a 106.68% 90 day share price return, alongside a 44.06% 1...
NYSE:BDC
NYSE:BDCElectronic

Belden (BDC) Could Be 11% Undervalued Following Analyst Optimism

Analyst sentiment around Belden (BDC) has turned more optimistic recently, with improved consensus earnings estimates and a stronger analyst ranking, which appears to be drawing fresh attention to the stock. See our latest analysis for Belden. Belden’s recent analyst upgrade comes after a strong run in the share price, with a 30-day share price return of 33.85% and a 3-year total shareholder return of 60.07%, which suggests momentum has been building around the current US$135.90 level. If you...
NasdaqGS:CHRD
NasdaqGS:CHRDOil and Gas

Is Chord Energy (CHRD) Undervalued On Strong Q2 Results And A Richer Payout Plan?

Chord Energy (CHRD) just paired strong second quarter earnings with higher oil production, fresh guidance, and an updated capital return plan, giving you several new data points to weigh the stock. See our latest analysis for Chord Energy. The latest Q2 update, dividend affirmation, and ongoing buybacks have arrived against a strong backdrop for Chord Energy, with the share price up 45.04% year to date, giving back 7.46% over 3 months, and delivering a 5 year total shareholder return of...
NasdaqGS:ASTE
NasdaqGS:ASTEMachinery

Tariff Enforcement Could Lift Astec Stock And Other U.S. Manufacturers

Tariffs were meant to raise cash for the government, yet rising trade fraud and tariff evasion now sit at the center of the story. That shift could reshape which U.S.-listed manufacturers benefit as stricter enforcement makes underpriced imports harder to sustain. This article walks through three stocks exposed to these trade and enforcement trends so you can decide how, or if, they fit into your watchlist. The three stocks covered below are just a starting sample, and the full screen...
NasdaqGS:MRX
NasdaqGS:MRXCapital Markets

Marex Group (MRX) Is Up 16.9% After Earnings Jump And New Bond Issuance - Has The Bull Case Changed?

Marex Group Limited recently completed two fixed-income offerings, issuing 5.00% senior unsecured Eurodollar notes due August 31, 2028 and 5.80% senior unsecured Eurodollar notes due September 2, 2031, while also affirming a quarterly dividend of US$0.1600 per share. For the half year ended June 30, 2026, Marex Group reported net income of US$268.0 million, up from US$149.2 million a year earlier, highlighting how infrastructure-intensive segments and acquisition activity are reshaping its...
NYSE:DNOW
NYSE:DNOWTrade Distributors

U.S. Industrials That Could Gain From Reshoring And Brazil Tariffs

Trade friction between the U.S. and Brazil is reshaping where factories sit and who wins supply contracts, and that is putting fresh attention on U.S. industrial stocks that sell mostly at home. When tariffs shift the playing field, some companies suddenly look more competitive while others face new questions. This article walks through three stocks that appear aligned with this reshoring theme and how the latest headlines might matter for a diversified portfolio. The stocks covered below are...
NasdaqGS:SPCX
NasdaqGS:SPCXTelecom

SpaceX (SPCX) Takes Over A $60 Billion Coding Startup

Space Exploration Technologies (NasdaqGS: SPCX) closed a US$60b all stock acquisition of agentic coding startup Cursor, folding it into the xAI division. Cursor adds one of the world's largest professional developer communities, a substantial GPU fleet, and detailed data on developer interactions to SpaceX's AI stack. The deal ranks as the second largest venture backed acquisition on record and is framed as a key step in expanding Grok AI and broader AI services beyond aerospace. This kind...
NasdaqGS:RIVN
NasdaqGS:RIVNAuto

Rivian (RIVN) Stock Looks Stretched On Sales Despite Weaker 3 Year Returns

Rivian Automotive stock is coming off a mixed few years, with the share price falling 26.1% over three years even as shorter term returns have swung around, and the current checks suggest the stock is not especially cheap. At the recent US$15.36 close, the broader valuation work points to an overvalued profile rather than a clear bargain. Over the past three years, Rivian Automotive has delivered a 26.1% decline, which raises the bar for the current share price to be supported by stronger...
NasdaqGM:GPCR
NasdaqGM:GPCRPharmaceuticals

Is New CCO Hire And Pipeline Clarity Altering The Investment Case For Structure Therapeutics (GPCR)?

Earlier in August 2026, Structure Therapeutics appointed industry veteran John Berrios as Chief Commercial Officer and outlined upcoming aleniglipron trial readouts, while reporting a higher second-quarter net loss of US$106.16 million and basic loss per share of US$1.47 year on year. The combination of a commercially focused leadership hire from Novo Nordisk and detailed timelines for obesity and diabetes trials could influence how investors view Structure Therapeutics’ long-term...
NasdaqGS:ACIW
NasdaqGS:ACIWSoftware

ACI Worldwide (ACIW) Just Gave Investors Something To Think About

ACI Worldwide (ACIW) is back in focus after raising its full year 2026 revenue guidance and posting higher second quarter revenue and net income compared with a year earlier. Investors now have fresh numbers to assess. See our latest analysis for ACI Worldwide. The latest guidance upgrade and acquisition commentary comes after a mixed near term share price move, with the stock down 6.31% on a 1 month share price return but up 28.28% over 3 months and supported by a 3 year total shareholder...
NYSE:TEVA
NYSE:TEVAPharmaceuticals

Is Teva Pharmaceutical Industries (TEVA) A Bargain On Its TEV 408 Phase 2b Move?

Why Teva Pharmaceutical Industries Stock Is Back in Focus Teva Pharmaceutical Industries (NYSE:TEVA) has moved its anti IL-15 antibody TEV-'408 into a phase 2b trial for nonsegmental vitiligo after phase 1b data suggested repigmentation benefits and a favorable safety profile. The quarterly subcutaneous dosing schedule and targeted autoimmune mechanism set TEV-'408 apart from existing vitiligo treatments, which could influence how investors think about Teva Pharmaceutical Industries and its...
NasdaqGS:RKLB
NasdaqGS:RKLBAerospace & Defense

Rocket Lab Stock And Other Defense Names To Watch As Bond Yields Climb

Government bond yields in the US and Europe have pressed toward multi month highs as investors react to stubborn inflation signals and higher perceived risk in sovereign debt. When borrowing costs reset like this, investors often look harder at sectors tied to long cycle government and commercial contracts. The Aerospace And Defense screener helps you find companies in that space. This article highlights three stocks to watch. The stocks below are just a starting sample of this Aerospace And...
NasdaqGS:CBC
NasdaqGS:CBCBanks

Central Bancompany (CBC) Could Be 3% Undervalued On Results And $100 Million Buyback

Central Bancompany (CBC) shares are in focus after the company reported second quarter and six month 2026 results, announced a new US$100 million buyback plan, and affirmed its quarterly cash dividend. See our latest analysis for Central Bancompany. Central Bancompany’s share price has pulled back slightly in the past week, yet the 30 day share price return of 4.24% and year to date share price return of 36.98% suggest momentum has been building, reinforced by recent earnings, buyback and...
NasdaqGS:THRM
NasdaqGS:THRMAuto Components

Is Gentherm’s (THRM) New Value Stock Status Reframing Its Long-Term Investment Narrative?

Zacks recently named Gentherm (THRM) a Rank #1 (Strong Buy) value stock, citing its favorable Forward P/E and P/B ratios versus industry peers. This recognition highlights how Gentherm’s current valuation metrics contrast with its analyst-assessed earnings outlook, sharpening investor focus on its value profile. We’ll now examine how Gentherm’s new Strong Buy value recognition may influence its existing investment narrative and perceived long-term prospects. Find 50 companies with promising...
NYSE:LB
NYSE:LBReal Estate

LandBridge (LB) Looks Closer To Fair Value As Record Q2 And M&A Pipeline Draw Focus

LandBridge (LB) is drawing attention after its second quarter 2026 earnings, a quarterly dividend declaration, and fresh commentary on an active acquisition pipeline tied to its Delaware Basin surface and infrastructure portfolio. See our latest analysis for LandBridge. LandBridge's recent news on record Q2 2026 results, the ongoing conversion to a Texas corporation, and an active M&A pipeline comes alongside strong share price momentum, with a year to date share price return of 62.38% and a...
NYSE:CE
NYSE:CEChemicals

Celanese (CE) Reports Mixed Second Quarter Results, Is It A Bargain?

Celanese (CE) recently reported second quarter 2026 results that showed sales of US$2,752 million compared with US$2,532 million a year earlier, while net income and earnings per share declined over the same period. See our latest analysis for Celanese. Against this mixed earnings backdrop, Celanese's recent share price performance has been choppy. The company recorded a 1-day share price return of 3.07% and a 7-day share price return of 4.03%, contrasted by a 90-day share price decline of...
NasdaqCM:APPS
NasdaqCM:APPSSoftware

Digital Turbine (APPS) Is Down 13.2% After Raising 2027 Revenue Guidance And Narrowing Losses – Has The Bull Case Changed?

Digital Turbine, Inc. reported past first-quarter 2026 results with sales of US$165.98 million versus US$130.93 million a year earlier, while trimming its net loss to US$3.16 million from US$14.10 million and reducing basic and diluted loss per share from US$0.13 to US$0.03. The company also raised its revenue guidance for fiscal 2027 to a range of US$650 million to US$670 million, signaling management’s increased confidence in the business following improved quarterly performance. We’ll now...
NasdaqCM:QUBT
NasdaqCM:QUBTTech

Quantum Computing (QUBT) Lifted Sales And Cut Its Loss, Is It Still A Bargain?

Earnings jump and acquisition plans put Quantum Computing in focus Quantum Computing (QUBT) has moved into the spotlight after reporting second quarter 2026 results that showed higher sales and a smaller net loss, alongside fresh comments about potential acquisitions and continued investment in its business. See our latest analysis for Quantum Computing. Quantum Computing shares have pulled back year to date, with an 18.17% share price decline and a 41.19% fall in the 1-year total shareholder...
NYSE:AMG
NYSE:AMGCapital Markets

Affiliated Managers Group (AMG) Just Gave Investors Something To Think About

Affiliated Managers Group (AMG) moved back into focus after its second quarter update, which combined higher reported sales and net income with a fresh cash dividend declaration and continued share repurchases. See our latest analysis for Affiliated Managers Group. The second quarter update landed after a strong run for Affiliated Managers Group, with the share price up 27.4% over the past 90 days and a year to date share price return of 29.6%. The 1 year total shareholder return of 71.2% and...
NasdaqGS:CYTK
NasdaqGS:CYTKBiotechs

Will MYQORZO Traction Amid Weaker Q2 2026 Results Change Cytokinetics' (CYTK) Narrative

Cytokinetics, Incorporated previously reported second-quarter 2026 results showing revenue of US$28.62 million versus US$66.77 million a year earlier, alongside a wider net loss of US$198.76 million and higher loss per share. Despite these weaker financials, the company highlighted meaningful commercial traction for MYQORZO and progress toward expanding its late-stage cardiology portfolio, which may matter more for how investors assess its long-term potential. Next, we’ll examine how...
NYSE:PFSI
NYSE:PFSIDiversified Financial

How Investors May Respond To PennyMac Financial Services (PFSI) Legal Probe Over Alleged Misleading Disclosures

In the past few days, Rosen Law Firm announced an investigation into potential securities claims against PennyMac Financial Services, following allegations that the company may have provided materially misleading business information amid a significant drop in servicing segment pretax income. This legal scrutiny introduces fresh uncertainty around PennyMac’s past disclosures and risk controls, raising questions about how resilient its business model and reporting practices may be under...
NYSE:MAA
NYSE:MAAResidential REITs

Mid America Apartment Communities (MAA) And The Sun Belt Case For A Cheap Valuation

National Healthcare Properties has appointed former Mid-America Apartment Communities (MAA) Chief Financial Officer Albert M. Campbell to its board and audit committee. This move reconnects investors with MAA’s long-serving finance leadership profile. See our latest analysis for Mid-America Apartment Communities. For Mid-America Apartment Communities, the recent appointment of its former long-serving CFO to another REIT board comes against a mixed performance backdrop, with a 90 day share...
NYSE:NPO
NYSE:NPOMachinery

Enpro (NPO) Moved Higher, What Is Behind The Attention Now?

What Enpro’s Updated Outlook Means For Investors Enpro (NPO) raised its 2026 earnings guidance on 4 August 2026, now projecting revenue growth of 14% to 16% compared to 10% to 14% a year ago. This update followed the company’s second quarter earnings release. For investors, the combination of refreshed guidance and recent results provides a clearer snapshot of how Enpro’s current operations in sealing and advanced surface technologies are feeding into near term expectations. See our latest...
NYSE:ARDT
NYSE:ARDTHealthcare

Why Ardent Health (ARDT) Is Down 5.5% After Cutting 2026 Guidance And Fueling Options Jitters - And What's Next

In the past quarter, Ardent Health, Inc. reported second-quarter 2026 sales of US$1,622.25 million and net income of US$16.9 million, alongside lower full-year 2026 earnings guidance and updated expectations for total revenue between US$6.40 billion and US$6.70 billion. Despite softer earnings and trimmed guidance, Ardent continued repurchasing shares under its existing buyback and drew heightened attention in the options market, where elevated implied volatility on certain contracts...